Our Pipeline

Publications

05 Jul 2019

Linzagolix for Treating Endometriosis-Associated Pain: Efficacy and Safety Results from a Randomized, Placebo-Controlled, Multinational, Phase 2b Dose-Ranging Trial

Bestel E.; Humberstone A.; Lecomte V.; Dubouloz R.; Terrill P.; Donnez J.; Taylor H.; Taylor R.; Loumaye E.

ESHRE Annual Conference, 23-26 June 2019, Vienna, Austria - O-141

20 May 2019

The Effect of Linzagolix on Bone Mineral Density (BMD): Safety Results From a Dose-Ranging Trial

Elke Bestel, Andrew Humberstone, Veronique Lecomte, Ernest Loumaye, Jean-Pierre Gotteland, James A. Simon

ACOG Annual Conference, 03-06 May 2019, Nashville, TN

04 Dec 2017

GnRH Receptor Antagonist Mono- And Combination Therapy With E2/NETA Add-Back - Pharmacodynamics And Safety Of OBE2109

Pohl O, Marchand L, Fawkes N, Gotteland JP, Loumaye E.

J Clin Endocrinol Metab. 2018 Feb 1;103(2):497-504. doi: 10.1210/jc.2017-01875

30 Mar 2017

THE 'ART' OF WOMEN'S HEALTH - Add back or not add back? Obseva: Both options good as UF, endo trials continue

Randy Osborne

Requires a subscription.

Media Contact

Switzerland & Europe:

Christophe Lamps
Dynamics Group
+41 79 476 26 87
cla@dynamicsgroup.ch

U.S.:

Marion Janic
RooneyPartners LLC
+1 212-223-4017
mjanic@rooneyco.com